Search

Your search keyword '"Kastelijn, Elisabeth A."' showing total 35 results
Start Over Author "Kastelijn, Elisabeth A."
35 results on '"Kastelijn, Elisabeth A."'

1. SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer

Author

Abdel-Karim, Isam, Abdelsalam, Mahmoud, Addeo, Alfredo, Aguado, Carlos, Alexander, Patrick, Alt, Jürgen, Azzi, Georges, Balaraman, Rama, Biesma, Bonne, Blackhall, Fiona, Bohnet, Sabine, Boleti, Ekaterini, Borghaei, Hossein, Bradbury, Penelope, Brighenti, Matteo, Campbell, Nicholas, Campbell, Toby, Canon, Jean-Luc, Cappuzzo, Federico, Costa, Enric Carcereny, Cavanna, Luigi, Cetnar, Jeremy, Chella, Antonio, Chouaid, Christos, Christoph, Daniel, Castán, Javier Cortés, Dakhil, Shaker, de Castro Carpeño, Francisco Javier, de Marinis, Filippo, Delmonte, Angelo, Demedts, Ingel, Demey, Wim, Dits, Joyce, del Pilar Diz Taín, Maria, Gómez, Manuel Dómine, Dorius, Timothy, Dumoulin, Daphne, Duruisseaux, Michaël, Eaton, Keith, González, Emilio Esteban, Evans, Devon, Faehling, Martin, Farrell, Nicholas, Feinstein, Trevor, Font, Enriqueta Felip, Garcia Campelo, Maria Rosario, Garon, Edward, Garrido López, María Pilar, Germonpré, Paul, Gersten, Todd, Cao, Maria Gonzalez, Gopaluni, Srivalli, Greillier, Laurent, Grossi, Francesco, Guisier, Florian, Gurubhagavatula, Sarada, Calderón, Vanesa Gutiérrez, Hakimian, David, Hall, Richard, Jr., Hao, Desirée, Harris, Ronald, Hashemi, Sayed, He, Kai, Hendriks, Lizza, Huang, Chao, Ibrahim, Emad, Jain, Sharad, Johnson, Melissa, Jones, Benjamin, Jones, Monte, Juan Vidal, Óscar José, Juergens, Rosalyn, Kaderbhai, Courèche, Kastelijn, Elisabeth A (Lisanne), Keresztes, Roger, Kio, Ebenezer, Kokowski, Konrad, Konduri, Kartik, Kulkarni, Swati, Kuon, Jonas, Kurkjian, Carla, Labbé, Catherine, Lerner, Rachel, Lim, Farah, Madroszyk-Flandin, Anne, Marathe, Omkar, Martincic, Danko, McClay, Edward, McIntyre, Kristi, Mekhail, Tarek, Misino, Andrea, Molinier, Olivier, Morabito, Alessandro, Morócz, Éva, Müller, Veronika, Nagy, Tünde, Nguyen, Anthony V., Nidhiry, Emmanuel, Okazaki, Ian, Ortega-Granados, Ana Laura, Ostoros, Gyula, Oubre, David, Owen, Scott, Pachipala, Krishna, Park, David, Patel, Pareshkumar, Percent, Ivor, Pérol, Maurice, Peters, Solange, Piet, Berber, Planchard, David, Polychronis, Andreas, Aix, Santiago Ponce, Pons-Tostivint, Elvire, Popat, Sanjaykumar, Pulla, Mariano Provencio, Quantin, Xavier, Quéré, Gilles, Rafique, Noman, Ramaekers, Ryan, Reck, Martin, Reiman, Anthony, Reinmuth, Niels, Reynolds, Craig, Rodríguez-Abreu, Delvys, Romano, Gianpiero, Roque, Tammy, Salzberg, Matthew, Sanborn, Rachel, Sandiego, Sergio, Schaefer, Eric, Schreeder, Marshall, Seetharamu, Nagashree, Seneviratne, Lasika, Shah, Purvi, Shunyakov, Leonid, Slater, Dennis, Parra, Hector Soto, Stigt, Johannes, Stilwill, Joseph, Su, Jingdong, Surmont, Veerle, Swink, Alicia, Szalai, Zsuzsanna, Talbot, Toby, Garcia, Alvaro Taus, Theelen, Willemijn, Thompson, Jonathan, Tiseo, Marcello, Uprety, Dipesh, Uyeki, James, van der Leest, Kornelius Cor, Van Ho, Anthony, van Putten, John, Estévez, Sergio Vázquez, Veatch, Andrea, Vergnenègre, Alain, Ward, Patrick, Weise, Amy, Weiss, Matthias, Whitehurst, Matthew, Zai, Silvia, Zalcman, Gérard, Zuniga, Richard, Borghaei, H., de Marinis, F., Dumoulin, D., Reynolds, C., Theelen, W.S.M.E., Percent, I., Gutierrez Calderon, V., Johnson, M.L., Madroszyk-Flandin, A., Garon, E.B., He, K., Planchard, D., Reck, M., Popat, S., Herbst, R.S., Leal, T.A., Shazer, R.L., Yan, X., Harrigan, R., and Peters, S.

Published
2024
Full Text
View/download PDF

5. SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer

Author

Borghaei, H., primary, de Marinis, F., additional, Dumoulin, D., additional, Reynolds, C., additional, Theelen, W.S.M.E., additional, Percent, I., additional, Gutierrez Calderon, V., additional, Johnson, M.L., additional, Madroszyk-Flandin, A., additional, Garon, E.B., additional, He, K., additional, Planchard, D., additional, Reck, M., additional, Popat, S., additional, Herbst, R.S., additional, Leal, T.A., additional, Shazer, R.L., additional, Yan, X., additional, Harrigan, R., additional, Peters, S., additional, Abdel-Karim, Isam, additional, Abdelsalam, Mahmoud, additional, Addeo, Alfredo, additional, Aguado, Carlos, additional, Alexander, Patrick, additional, Alt, Jürgen, additional, Azzi, Georges, additional, Balaraman, Rama, additional, Biesma, Bonne, additional, Blackhall, Fiona, additional, Bohnet, Sabine, additional, Boleti, Ekaterini, additional, Borghaei, Hossein, additional, Bradbury, Penelope, additional, Brighenti, Matteo, additional, Campbell, Nicholas, additional, Campbell, Toby, additional, Canon, Jean-Luc, additional, Cappuzzo, Federico, additional, Costa, Enric Carcereny, additional, Cavanna, Luigi, additional, Cetnar, Jeremy, additional, Chella, Antonio, additional, Chouaid, Christos, additional, Christoph, Daniel, additional, Castán, Javier Cortés, additional, Dakhil, Shaker, additional, de Castro Carpeño, Francisco Javier, additional, de Marinis, Filippo, additional, Delmonte, Angelo, additional, Demedts, Ingel, additional, Demey, Wim, additional, Dits, Joyce, additional, del Pilar Diz Taín, Maria, additional, Gómez, Manuel Dómine, additional, Dorius, Timothy, additional, Dumoulin, Daphne, additional, Duruisseaux, Michaël, additional, Eaton, Keith, additional, González, Emilio Esteban, additional, Evans, Devon, additional, Faehling, Martin, additional, Farrell, Nicholas, additional, Feinstein, Trevor, additional, Font, Enriqueta Felip, additional, Garcia Campelo, Maria Rosario, additional, Garon, Edward, additional, Garrido López, María Pilar, additional, Germonpré, Paul, additional, Gersten, Todd, additional, Cao, Maria Gonzalez, additional, Gopaluni, Srivalli, additional, Greillier, Laurent, additional, Grossi, Francesco, additional, Guisier, Florian, additional, Gurubhagavatula, Sarada, additional, Calderón, Vanesa Gutiérrez, additional, Hakimian, David, additional, Hall, Richard, additional, Hao, Desirée, additional, Harris, Ronald, additional, Hashemi, Sayed, additional, He, Kai, additional, Hendriks, Lizza, additional, Huang, Chao, additional, Ibrahim, Emad, additional, Jain, Sharad, additional, Johnson, Melissa, additional, Jones, Benjamin, additional, Jones, Monte, additional, Juan Vidal, Óscar José, additional, Juergens, Rosalyn, additional, Kaderbhai, Courèche, additional, Kastelijn, Elisabeth A (Lisanne), additional, Keresztes, Roger, additional, Kio, Ebenezer, additional, Kokowski, Konrad, additional, Konduri, Kartik, additional, Kulkarni, Swati, additional, Kuon, Jonas, additional, Kurkjian, Carla, additional, Labbé, Catherine, additional, Lerner, Rachel, additional, Lim, Farah, additional, Madroszyk-Flandin, Anne, additional, Marathe, Omkar, additional, Martincic, Danko, additional, McClay, Edward, additional, McIntyre, Kristi, additional, Mekhail, Tarek, additional, Misino, Andrea, additional, Molinier, Olivier, additional, Morabito, Alessandro, additional, Morócz, Éva, additional, Müller, Veronika, additional, Nagy, Tünde, additional, Nguyen, Anthony V., additional, Nidhiry, Emmanuel, additional, Okazaki, Ian, additional, Ortega-Granados, Ana Laura, additional, Ostoros, Gyula, additional, Oubre, David, additional, Owen, Scott, additional, Pachipala, Krishna, additional, Park, David, additional, Patel, Pareshkumar, additional, Percent, Ivor, additional, Pérol, Maurice, additional, Peters, Solange, additional, Piet, Berber, additional, Planchard, David, additional, Polychronis, Andreas, additional, Aix, Santiago Ponce, additional, Pons-Tostivint, Elvire, additional, Popat, Sanjaykumar, additional, Pulla, Mariano Provencio, additional, Quantin, Xavier, additional, Quéré, Gilles, additional, Rafique, Noman, additional, Ramaekers, Ryan, additional, Reck, Martin, additional, Reiman, Anthony, additional, Reinmuth, Niels, additional, Reynolds, Craig, additional, Rodríguez-Abreu, Delvys, additional, Romano, Gianpiero, additional, Roque, Tammy, additional, Salzberg, Matthew, additional, Sanborn, Rachel, additional, Sandiego, Sergio, additional, Schaefer, Eric, additional, Schreeder, Marshall, additional, Seetharamu, Nagashree, additional, Seneviratne, Lasika, additional, Shah, Purvi, additional, Shunyakov, Leonid, additional, Slater, Dennis, additional, Parra, Hector Soto, additional, Stigt, Johannes, additional, Stilwill, Joseph, additional, Su, Jingdong, additional, Surmont, Veerle, additional, Swink, Alicia, additional, Szalai, Zsuzsanna, additional, Talbot, Toby, additional, Garcia, Alvaro Taus, additional, Theelen, Willemijn, additional, Thompson, Jonathan, additional, Tiseo, Marcello, additional, Uprety, Dipesh, additional, Uyeki, James, additional, van der Leest, Kornelius Cor, additional, Van Ho, Anthony, additional, van Putten, John, additional, Estévez, Sergio Vázquez, additional, Veatch, Andrea, additional, Vergnenègre, Alain, additional, Ward, Patrick, additional, Weise, Amy, additional, Weiss, Matthias, additional, Whitehurst, Matthew, additional, Zai, Silvia, additional, Zalcman, Gérard, additional, and Zuniga, Richard, additional

Published
2023
Full Text
View/download PDF

9. Life-prolonging treatment restrictions and outcomes in patients with cancer and COVID-19:an update from the Dutch Oncology COVID-19 Consortium

Author

de Joode, Karlijn, Tol, Jolien, Hamberg, Paul, Cloos, Marissa, Kastelijn, Elisabeth A., Borgers, Jessica S.W., Nuij, Veerle J.A.A., Klaver, Yarne, Herder, Gerarda J.M., Mutsaers, Pim G.N.J., Dumoulin, Daphne W., Oomen-de Hoop, Esther, van Diemen, Nico G.J., Libourel, Eduard J., Geraedts, Erica J., Bootsma, Gerben P., van der Leest, Cor H., Peerdeman, Anne L., Herbschleb, Karin H., Visser, Otto J., Bloemendal, Haiko J., van Laarhoven, Hanneke W.M., de Vries, Elisabeth G.E., Hendriks, Lizza E.L., Beerepoot, Laurens V., Westgeest, Hans M., van den Berkmortel, Franchette W.P.J., Dingemans, Anne Marie C., van der Veldt, Astrid A.M., van Leeuwen, L., van der Meer, F. S., Tiemessen, M. A., van Diepen, D. M., Brocken, P., Drooger, J. C., de Groot, J. W.B., Stigt, J. A., Slingerland, M., Haberkorn, B. C.M., Aarts, M. J.B., Youssef, M., Faber, L. M., van de Wetering, R. A.W., Bard, M. P.L., Douma, G., Suijkerbuijk, K. P.M., Bakker, S. D., de Jong, W. K., Staal, A. J., Franken, B., de Joode, Karlijn, Tol, Jolien, Hamberg, Paul, Cloos, Marissa, Kastelijn, Elisabeth A., Borgers, Jessica S.W., Nuij, Veerle J.A.A., Klaver, Yarne, Herder, Gerarda J.M., Mutsaers, Pim G.N.J., Dumoulin, Daphne W., Oomen-de Hoop, Esther, van Diemen, Nico G.J., Libourel, Eduard J., Geraedts, Erica J., Bootsma, Gerben P., van der Leest, Cor H., Peerdeman, Anne L., Herbschleb, Karin H., Visser, Otto J., Bloemendal, Haiko J., van Laarhoven, Hanneke W.M., de Vries, Elisabeth G.E., Hendriks, Lizza E.L., Beerepoot, Laurens V., Westgeest, Hans M., van den Berkmortel, Franchette W.P.J., Dingemans, Anne Marie C., van der Veldt, Astrid A.M., van Leeuwen, L., van der Meer, F. S., Tiemessen, M. A., van Diepen, D. M., Brocken, P., Drooger, J. C., de Groot, J. W.B., Stigt, J. A., Slingerland, M., Haberkorn, B. C.M., Aarts, M. J.B., Youssef, M., Faber, L. M., van de Wetering, R. A.W., Bard, M. P.L., Douma, G., Suijkerbuijk, K. P.M., Bakker, S. D., de Jong, W. K., Staal, A. J., and Franken, B.

Abstract

Aim of the study: The coronavirus disease 2019 (COVID-19) pandemic significantly impacted cancer care. In this study, clinical patient characteristics related to COVID-19 outcomes and advanced care planning, in terms of non-oncological treatment restrictions (e.g. do-not-resuscitate codes), were studied in patients with cancer and COVID-19. Methods: The Dutch Oncology COVID-19 Consortium registry was launched in March 2020 in 45 hospitals in the Netherlands, primarily to identify risk factors of a severe COVID-19 outcome in patients with cancer. Here, an updated analysis of the registry was performed, and treatment restrictions (e.g. do-not-intubate codes) were studied in relation to COVID-19 outcomes in patients with cancer. Oncological treatment restrictions were not taken into account. Results: Between 27th March 2020 and 4th February 2021, 1360 patients with cancer and COVID-19 were registered. Follow-up data of 830 patients could be validated for this analysis. Overall, 230 of 830 (27.7%) patients died of COVID-19, and 60% of the remaining 600 patients with resolved COVID-19 were admitted to the hospital. Patients with haematological malignancies or lung cancer had a higher risk of a fatal outcome than other solid tumours. No correlation between anticancer therapies and the risk of a fatal COVID-19 outcome was found. In terms of end-of-life communication, 50% of all patients had restrictions regarding life-prolonging treatment (e.g. do-not-intubate codes). Most identified patients with treatment restrictions had risk factors associated with fatal COVID-19 outcome. Conclusion: There was no evidence of a negative impact of anticancer therapies on COVID-19 outcomes. Timely end-of-life communication as part of advanced care planning could save patients from prolonged suffering and decrease burden in intensive care units. Early discussion of treatment restrictions should therefore be part of routine oncological care, especially during the COVID-19 pandemic.

Published
2022

10. Life-prolonging treatment restrictions and outcomes in patients with cancer and COVID-19: an update from the Dutch Oncology COVID-19 Consortium

Author

MS Medische Oncologie, Infection & Immunity, Cancer, Longziekten, de Joode, Karlijn, Tol, Jolien, Hamberg, Paul, Cloos, Marissa, Kastelijn, Elisabeth A., Borgers, Jessica S.W., Nuij, Veerle J.A.A., Klaver, Yarne, Herder, Gerarda J.M., Mutsaers, Pim G.N.J., Dumoulin, Daphne W., Oomen-de Hoop, Esther, van Diemen, Nico G.J., Libourel, Eduard J., Geraedts, Erica J., Bootsma, Gerben P., van der Leest, Cor H., Peerdeman, Anne L., Herbschleb, Karin H., Visser, Otto J., Bloemendal, Haiko J., van Laarhoven, Hanneke W.M., de Vries, Elisabeth G.E., Hendriks, Lizza E.L., Beerepoot, Laurens V., Westgeest, Hans M., van den Berkmortel, Franchette W.P.J., Haanen, John B.A.G., Dingemans, Anne Marie C., van der Veldt, Astrid A.M., Becker-Commissaris, A., Terheggen, F., van den Borne, B. E.E.M., van Warmerdam, L. J.C., van Leeuwen, L., van der Meer, F. S., Tiemessen, M. A., van Diepen, D. M., Strobbe, L., Koekkoek, J. A.F., Brocken, P., Drooger, J. C., de Groot, J. W.B., Aarts, M. J.B., Cirkel, G. A., Claessens, N. J.M., Jalving, M., Suijkerbuijk, K. P.M., van Lindert, A. S.R., Bakker, S. D., MS Medische Oncologie, Infection & Immunity, Cancer, Longziekten, de Joode, Karlijn, Tol, Jolien, Hamberg, Paul, Cloos, Marissa, Kastelijn, Elisabeth A., Borgers, Jessica S.W., Nuij, Veerle J.A.A., Klaver, Yarne, Herder, Gerarda J.M., Mutsaers, Pim G.N.J., Dumoulin, Daphne W., Oomen-de Hoop, Esther, van Diemen, Nico G.J., Libourel, Eduard J., Geraedts, Erica J., Bootsma, Gerben P., van der Leest, Cor H., Peerdeman, Anne L., Herbschleb, Karin H., Visser, Otto J., Bloemendal, Haiko J., van Laarhoven, Hanneke W.M., de Vries, Elisabeth G.E., Hendriks, Lizza E.L., Beerepoot, Laurens V., Westgeest, Hans M., van den Berkmortel, Franchette W.P.J., Haanen, John B.A.G., Dingemans, Anne Marie C., van der Veldt, Astrid A.M., Becker-Commissaris, A., Terheggen, F., van den Borne, B. E.E.M., van Warmerdam, L. J.C., van Leeuwen, L., van der Meer, F. S., Tiemessen, M. A., van Diepen, D. M., Strobbe, L., Koekkoek, J. A.F., Brocken, P., Drooger, J. C., de Groot, J. W.B., Aarts, M. J.B., Cirkel, G. A., Claessens, N. J.M., Jalving, M., Suijkerbuijk, K. P.M., van Lindert, A. S.R., and Bakker, S. D.

Published
2022

12. Life-prolonging treatment restrictions and outcomes in patients with cancer and COVID-19: an update from the Dutch Oncology COVID-19 Consortium

Author

de Joode, Karlijn, primary, Tol, Jolien, additional, Hamberg, Paul, additional, Cloos, Marissa, additional, Kastelijn, Elisabeth A., additional, Borgers, Jessica S.W., additional, Nuij, Veerle J.A.A., additional, Klaver, Yarne, additional, Herder, Gerarda J.M., additional, Mutsaers, Pim G.N.J., additional, Dumoulin, Daphne W., additional, Oomen-de Hoop, Esther, additional, van Diemen, Nico G.J., additional, Libourel, Eduard J., additional, Geraedts, Erica J., additional, Bootsma, Gerben P., additional, van der Leest, Cor H., additional, Peerdeman, Anne L., additional, Herbschleb, Karin H., additional, Visser, Otto J., additional, Bloemendal, Haiko J., additional, van Laarhoven, Hanneke W.M., additional, de Vries, Elisabeth G.E., additional, Hendriks, Lizza E.L., additional, Beerepoot, Laurens V., additional, Westgeest, Hans M., additional, van den Berkmortel, Franchette W.P.J., additional, Haanen, John B.A.G., additional, Dingemans, Anne-Marie C., additional, van der Veldt, Astrid A.M., additional, Becker-Commissaris, A., additional, Terheggen, F., additional, van den Borne, B.E.E.M., additional, van Warmerdam, L.J.C., additional, van Leeuwen, L., additional, van der Meer, F.S., additional, Tiemessen, M.A., additional, van Diepen, D.M., additional, Strobbe, L., additional, Koekkoek, J.A.F., additional, Brocken, P., additional, Drooger, J.C., additional, Heller, R., additional, de Groot, J.W.B., additional, Stigt, J.A., additional, Pitz, C.C.M., additional, Slingerland, M., additional, Borm, F.J., additional, Haberkorn, B.C.M., additional, van 't Westeinde, S.C., additional, Aarts, M.J.B., additional, van Putten, J.W.G., additional, Youssef, M., additional, Cirkel, G.A., additional, van Rooijen, C.R., additional, Citgez, E., additional, Barlo, N.P., additional, Scholtes, B.M.J., additional, Koornstra, R.H.T., additional, Claessens, N.J.M., additional, Faber, L.M., additional, Rikers, C.H., additional, van de Wetering, R.A.W., additional, Veurink, G.L., additional, Bouter, B.W., additional, Houtenbos, I., additional, Bard, M.P.L., additional, Douma, G., additional, Jalving, M., additional, Hiltermann, T.J.N., additional, Schuurbiers-Siebers, O.C.J., additional, Suijkerbuijk, K.P.M., additional, van Lindert, A.S.R., additional, van de Wouw, A.J., additional, van den Boogaart, V.E.M., additional, Bakker, S.D., additional, Looysen, E., additional, de Jong, W.K., additional, Siemerink, E.J.M., additional, Staal, A.J., additional, Franken, B., additional, and van Geffen, W.H., additional

Published
2022
Full Text
View/download PDF

13. Development and evaluation of a real-world outcomes-based tool to support informed clinical decision making in the palliative treatment of patients with metastatic nsclc

Author

Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Cramer-Van der Welle, Christine M., Kastelijn, Elisabeth A., Plouvie, Bram C., Van Uden-Kraan, Cornelia F., Schramel, Franz M.N.H., Groen, Harry J.M., Van de Garde, Ewoudt M.W., Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Cramer-Van der Welle, Christine M., Kastelijn, Elisabeth A., Plouvie, Bram C., Van Uden-Kraan, Cornelia F., Schramel, Franz M.N.H., Groen, Harry J.M., and Van de Garde, Ewoudt M.W.

Published
2021

15. sj-pdf-1-mdm-10.1177_0272989X20978167 – Supplemental material for Cost-Effectiveness of Surveillance Scanning Strategies after Curative Treatment of Non–Small-Cell Lung Cancer

Author

Wolff, Henri B., Alberts, Leonie, Kastelijn, Elisabeth A., Sharouni, Sherif Y. El, Schramel, Franz M. N. H., and Coupé, Veerle M. H.

Subjects
111708 Health and Community Services, 111799 Public Health and Health Services not elsewhere classified, 160807 Sociological Methodology and Research Methods, FOS: Health sciences, FOS: Sociology
Abstract

Supplemental material, sj-pdf-1-mdm-10.1177_0272989X20978167 for Cost-Effectiveness of Surveillance Scanning Strategies after Curative Treatment of Non–Small-Cell Lung Cancer by Henri B. Wolff, Leonie Alberts, Elisabeth A. Kastelijn, Sherif Y. El Sharouni, Franz M. N. H. Schramel and Veerle M. H. Coupé in Medical Decision Making

Published
2020
Full Text
View/download PDF

19. Cost-effectiveness of stereotactic body radiation therapy versus video assisted thoracic surgery in medically operable stage I non-small cell lung cancer: A modeling study

Author

Wolff, Henri B., primary, Alberts, Leonie, additional, van der Linden, Naomi, additional, Bongers, Mathilda L., additional, Verstegen, Naomi E., additional, Lagerwaard, Frank J., additional, Hofman, Frederik N., additional, Uyl-de Groot, Carin A., additional, Senan, Suresh, additional, El Sharouni, Sherif Y., additional, Kastelijn, Elisabeth A., additional, Schramel, Franz M.N.H., additional, and Coupé, Veerle M.H., additional

Published
2020
Full Text
View/download PDF

20. Cost-Effectiveness of Surveillance Scanning Strategies after Curative Treatment of Non–Small-Cell Lung Cancer.

Author

Wolff, Henri B., Alberts, Leonie, Kastelijn, Elisabeth A., El Sharouni, Sherif Y., Schramel, Franz M. N. H., and Coupé, Veerle M. H.

Abstract

Background: After curative treatment of primary non–small-cell lung cancer (NSCLC), patients undergo intensive surveillance with the aim to detect recurrences from the primary tumor or metachronous second primary lung cancer as early as possible and improve overall survival. However, the benefit of surveillance is debated. Available evidence is of low quality and conflicting. Microsimulation modeling facilitates the exploration of the impact of different surveillance strategies and provides insight into the cost-effectiveness of surveillance. Methods: A microsimulation model was used to simulate a range of computed tomography (CT)–based surveillance schedules, differing in the frequency and duration of CT surveillance. The impact on survival, quality-adjusted life-years, costs, and cost-effectiveness of each schedule was assessed. Results: Ten of 108 strategies formed the cost-effectiveness frontier; that is, these were the strategies with the optimal cost-health benefit balance. Per person, the discounted QALYs of these strategies varied between 5.72 and 5.81 y, and discounted costs varied between €9892 and €19,259. Below a willingness-to-pay threshold of €50,000/QALY, no scanning is the preferred option. For a willingness-to-pay threshold of €80,000/QALY, surveillance scanning every 2 y starting 1 y after curative treatment becomes the best option, with €11,860 discounted costs and 5.76 discounted QALYs per person. The European Society for Medical Oncology guideline strategy was more expensive and less effective than several other strategies. Conclusion: Model simulations suggest that limited CT surveillance scanning after the treatment of primary NSCLC is cost-effective, but the incremental health-benefit remains marginal. However, model simulations do suggest that the guideline strategy is not cost-effective. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

21. Differences in Longitudinal Health Utility between Stereotactic Body Radiation Therapy and Surgery in Stage I Non–Small Cell Lung Cancer

Author

Wolff, Henri B., primary, Alberts, Leonie, additional, Kastelijn, Elisabeth A., additional, Lissenberg-Witte, Birgit I., additional, Twisk, Jos W., additional, Lagerwaard, Frank J., additional, Senan, Suresh, additional, El Sharouni, Sherif Y., additional, Schramel, Franz M.N.H., additional, and Coupé, Veerle M.H., additional

Published
2018
Full Text
View/download PDF

25. Genetic Variation in Caveolin-1 Affects Survival After Lung Transplantation

Author

Vandermeulen, Elly, primary, Ruttens, David, additional, Verleden, Stijn E., additional, Vos, Robin, additional, Van Raemdonck, Dirk E., additional, Kastelijn, Elisabeth A., additional, Wauters, Els, additional, Lambrechts, Diether, additional, Nawrot, Tim S., additional, Cox, Bianca, additional, Verleden, Geert M., additional, and Vanaudenaerde, Bart M., additional

Published
2014
Full Text
View/download PDF

27. A genetic polymorphism in the CAV1 gene associates with the development of bronchiolitis obliterans syndrome after lung transplantation

Author

Kastelijn, Elisabeth A, primary, van Moorsel, Coline HM, additional, Kazemier, Karin M, additional, Roothaan, Suzan M, additional, Ruven, Henk JT, additional, Kwakkel-van Erp, Johanna M, additional, van de Graaf, Ed A, additional, Zanen, Pieter, additional, van Kessel, Diana A, additional, and Grutters, Jan C, additional

Published
2011
Full Text
View/download PDF

29. Genetic polymorphisms in MMP7 and reduced serum levels associate with the development of bronchiolitis obliterans syndrome after lung transplantation

Author

Kastelijn, Elisabeth A., primary, van Moorsel, Coline H., additional, Ruven, Henk J., additional, Karthaus, Vincent, additional, Kwakkel-van Erp, Johanna M., additional, van de Graaf, Ed A., additional, Zanen, Pieter, additional, van Kessel, Diana A., additional, Grutters, Jan C., additional, and van den Bosch, Jules M., additional

Published
2010
Full Text
View/download PDF

30. Polymorphisms in innate immunity genes associated with development of bronchiolitis obliterans after lung transplantation

Author

Kastelijn, Elisabeth A., primary, van Moorsel, Coline H.M., additional, Rijkers, Ger T., additional, Ruven, Henk J.T., additional, Karthaus, Vincent, additional, Kwakkel-van Erp, Johanna M., additional, van de Graaf, E.A., additional, Zanen, Pieter, additional, van Kessel, Diana A., additional, Grutters, Jan C., additional, and van den Bosch, Jules M.M., additional

Published
2010
Full Text
View/download PDF

31. The potential for deprescribing in a palliative oncology patient population: a cross-sectional study.

Author

van Merendonk LN, Peters BJM, Möhlmann JE, Hunting CB, Kastelijn EA, and van den Broek MPH

Subjects
Humans, Aged, Inappropriate Prescribing prevention & control, Cross-Sectional Studies, Potentially Inappropriate Medication List, Deprescriptions, Neoplasms drug therapy, Neoplasms epidemiology
Abstract

Objectives: The use of preventive medication in palliative oncology patients may be inappropriate due to limited life expectancy. Deprescribing tools are available but time-consuming and not always tailored to this specific population. Our primary goal was to identify potentially inappropriate medications (PIMs) in palliative oncology patients with a life expectancy of up to 2 years using an adapted deprescribing tool. Our secondary aim was to identify patient characteristics associated with the presence of PIMs., Methods: Oncology patients with a life expectancy of up to 2 years were included cross-sectionally. An adapted deprescribing tool was developed to identify PIMs. Logistic regression was used to identify factors associated with having PIMs., Results: A total of 218 patients were included in this study of which 56% had at least one PIM with a population mean of 1.1 PIM per patient. Most frequently defined PIMs were antihypertensive drugs and gastric acid inhibitors. Identification of PIMs by review took an estimated 5-10 min per patient. Polypharmacy, age >65 years and inpatient/outpatient status were found to be associated with having at least one PIM., Conclusions: Deprescribing is possible in more than half of palliative oncology patients with a life expectancy of up to 2 years. The adapted deprescribing tool used is non-time consuming and suitable for palliative oncology patients, regardless of age., Competing Interests: Competing interests: None declared., (© European Association of Hospital Pharmacists 2024. No commercial re-use. See rights and permissions. Published by BMJ.)

Published
2023
Full Text
View/download PDF

32. Utilization of Molecular Testing and Survival Outcomes of Treatment with First- or Second-line Tyrosine Kinase Inhibitors in Advanced Non-small Cell Lung Cancer in a Dutch Population.

Author

Sluga R, VAN DEN Borne BEEM, Roepman P, Peters BJM, Kastelijn EA, and Schramel FMNH

Subjects
Adult, Afatinib, Aged, Aged, 80 and over, Carcinoma, Non-Small-Cell Lung diagnosis, Carcinoma, Non-Small-Cell Lung genetics, Disease-Free Survival, Erlotinib Hydrochloride therapeutic use, Female, Gefitinib, Humans, Lung Neoplasms diagnosis, Lung Neoplasms genetics, Male, Middle Aged, Molecular Diagnostic Techniques methods, Netherlands, Quinazolines therapeutic use, Retrospective Studies, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Carcinoma, Non-Small-Cell Lung drug therapy, ErbB Receptors antagonists & inhibitors, ErbB Receptors genetics, Lung Neoplasms drug therapy, Protein Kinase Inhibitors therapeutic use
Abstract

Background/aim: Epidermal growth factor receptor (EGFR) mutation testing is standard-of-care for advanced non-small cell lung cancer (NSCLC). Outcomes of second-/third-line compared to first-line tyrosine kinase inhibitors (TKIs) have shown conflicting results. We investigated utilization of molecular diagnostics and the outcomes of treatment with first-/second-line TKIs in patients with advanced NSCLC., Materials and Methods: Retrospective analysis was carried out of 2,206 patients with stage IIIb/IV NSCLC treated between 2008 and 2014 in four hospitals in the Netherlands., Results: The rate of performing molecular diagnostics increased from 20.8% to 74.4% in the study period. The median overall survival of EGFR mutation-positive patients treated with TKIs was superior compared to EGFR mutation-negative patients treated with chemotherapy (720 vs. 274 days, p<0.0001). No difference in overall survival was found between EGFR mutation-positive patients treated only with TKIs compared to those treated with chemotherapy prior to TKIs, or upon progression under TKIs., Conclusion: The rate of EGFR testing has improved, increasing the number of patients eligible for targeted therapy. Chemotherapy, prior or subsequent to TKIs, for the treatment of EGFR mutation-positive patients, did not result in significantly better overall survival compared to that achieved with TKIs alone., (Copyright© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)

Published
2018
Full Text
View/download PDF

33. Changes in Pulmonary Function After Stereotactic Body Radiotherapy and After Surgery for Stage I and II Non-small Cell Lung Cancer, a Description of Two Cohorts.

Author

Alberts L, El Sharouni SY, Hofman FN, Van Putte BP, Tromp E, Van Vulpen M, Kastelijn EA, and Schramel FM

Subjects
Adult, Aged, Aged, 80 and over, Carcinoma, Non-Small-Cell Lung pathology, Cohort Studies, Female, Humans, Lung Neoplasms pathology, Male, Middle Aged, Neoplasm Staging, Retrospective Studies, Carcinoma, Non-Small-Cell Lung radiotherapy, Carcinoma, Non-Small-Cell Lung surgery, Lung Neoplasms radiotherapy, Lung Neoplasms surgery, Radiosurgery methods, Respiratory Function Tests methods
Abstract

Aim: To evaluate changes in pulmonary function tests (PFTs) at different follow-up durations after stereotactic body radiotherapy (SBRT) and surgery in stage I and II non-small-cell lung cancer (NSCLC)., Patients and Methods: Differences between pre-treatment- and follow-up PFTs were analyzed in 93 patients treated with surgery and 30 patients treated with SBRT for NSCLC. Follow-up durations were categorized into: early (0-9 months), middle (10-21 months) and late (≥22 months). Wilcoxon signed-rank test was used to analyze differences between pre-treatment and follow-up PFTs., Results: Forced expiratory volume in one second, forced vital capacity and diffusion capacity for carbon monoxide corrected for the actual hemoglobin level significantly diminished after surgery for all follow-up durations: 11-17% of predicted values. After SBRT, PFTs remained stable, but a declining trend of 6% (p=0.1) was observed after 22 months., Conclusion: SBRT might lead to less treatment-related toxicity measured by PFTs than surgery in both the short and long term., (Copyright© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.)

Published
2015

34. Clinical Outcomes in Early-stage NSCLC Treated with Stereotactic Body Radiotherapy Versus Surgical Resection.

Author

Kastelijn EA, El Sharouni SY, Hofman FN, Van Putte BP, Monninkhof EM, Van Vulpen M, and Schramel FM

Subjects
Adenocarcinoma mortality, Adenocarcinoma pathology, Adenocarcinoma surgery, Aged, Carcinoma, Large Cell mortality, Carcinoma, Large Cell pathology, Carcinoma, Large Cell surgery, Carcinoma, Non-Small-Cell Lung pathology, Carcinoma, Non-Small-Cell Lung surgery, Carcinoma, Squamous Cell mortality, Carcinoma, Squamous Cell pathology, Carcinoma, Squamous Cell surgery, Female, Follow-Up Studies, Humans, Lung Neoplasms mortality, Lung Neoplasms pathology, Lung Neoplasms surgery, Male, Neoplasm Recurrence, Local pathology, Neoplasm Recurrence, Local surgery, Neoplasm Staging, Prognosis, Retrospective Studies, Survival Rate, Carcinoma, Non-Small-Cell Lung mortality, Neoplasm Recurrence, Local mortality, Pneumonectomy mortality, Radiosurgery mortality, Thoracotomy mortality
Abstract

Background: Surgical resection is the treatment of first choice for patients with stage I-II non-small cell lung cancer (NSCLC). However, stereotactic body radiotherapy (SBRT) has been shown to be a good alternative treatment., Patients and Methods: Overall survival (OS), progression-free survival (PFS) and recurrence rates were compared between patients with stage I-II NSCLC treated with SBRT (n=53) and those treated with surgical resection (n=175). The propensity score method was used to correct for confounding by indication., Results: Before correction, the OS and PFS rates at 1 and 3 years were significantly different between SBRT and surgery, in favor of surgery. After correction, the OS and PFS after SBRT were not significantly different compared to surgery. The recurrence rates for the two treatments were also similar both before and after correction., Conclusion: This retrospective study showed that clinical outcomes after SBRT are equal to those after surgery in patients with stage I-II NSCLC., (Copyright© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.)

Published
2015

35. [Neurological complications caused by desmopressin in adults with nocturia].

Author

Steendam CM, Vincent HH, and Kastelijn EA

Subjects
Aged, 80 and over, Deamino Arginine Vasopressin therapeutic use, Female, Humans, Male, Middle Aged, Nocturia drug therapy, Deamino Arginine Vasopressin adverse effects, Hyponatremia chemically induced
Abstract

Desmopressin is occasionally used to reduce the frequency of nocturnal toilet visits. We describe an 86-year-old woman with nocturnal incontinence due to a urinary tract infection, and a 49-year-old man with frequent toilet visits in the night, known to consume excessive amounts of alcohol. They were admitted to hospital with neurological symptoms due to severe hyponatraemia, 114 and 102 mmol/l respectively, while using desmopressin. After the desmopressin had been discontinued and the fluid balance restored, they recovered completely. Hyponatraemia is inherent to the mechanism of action of desmopressin. Desmopressin should be prescribed only on sound indication, and risk factors for developing severe hyponatraemia should always be taken into consideration. Proper instruction and follow-up are important to prevent severe complications.

Published
2011

Catalog

Books, media, physical & digital resources
See catalog results